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In a large five-generation Polish family, late-onset ornithine transcarbamylase 
(OTC) deficiency in males segregated with the missense mutation A la208Thr 
(A208T), and all heterozygous females were asymptomatic. No other m uta­
tions were found in the coding sequences and intron-exon boundaries o f the 
OTC gene. Surprisingly, the mutation originated from the great-grandfather 
o f  the index patient who died at age 59 of liver carcinoma. He never had die­
tary restrictions or hyperammonemic spells throughout life and appears to be 
the oldest male reported with OTC deficiency. The index patient had a severe 
OTC deficiency (3% of normal). Eight males died suddenly at ages 4 months 
to 23 years (average 14 years) after a foudroyant episode triggered by a com ­
mon infection.The patients remained undiagnosed for 28 years because a m et­
abolic defect was not considered to be the cause of the acute episodes. 
Recognition of the familial pattern of inheritance was initially unnoticed since 
the patients were admitted to eight different hospitals. DNA analysis pre­
dicted that two ‘healthy’ boys also had OTC deficiency, which was confirmed 
by  abnormal results of allopurinol challenge tests. Initial suspicion of OTC 
deficiency in such families is complicated, since symptoms can develop at 
any age, or even remain absent. This obscures the typical pattern of X-linked 
inheritance in small families.
O.P. van Diggelen1, J . Zaremba2, 
Wang He1, J. L. M. Keulemans1,
A. M. Boer1, A. J . J . Reuser1,
M. G. E. M. Ausems5,
J. A. M. Smeitink6, J . Kowalczyk3, 
E. Pronicka4, D. Rokicki4,
E. Tarnowska-Dziduszko2,
A. L. J . Kneppers7 and E. Bakker7
1 Department of Clinical Genetics,
Erasmus University, Rotterdam, Rotterdam,
The Netherlands, department of Clinical 
Genetics, Institute of Psychiatry and Neurology, 
Warsaw, Poland, 3Medical Academy, Lublin, 
Poland, 4Child Health Centre, Warsaw, Poland, 
5Clinical Genetics Centre, Utrecht,
The Netherlands, department of Metabolic 
Diseases, Wilhelmina Children's Hospital, 
Utrecht, The Netherlands, department of Human 
Genetics, Leiden University, Leiden,
The Netherlands
Key words: asymptomatic -  late onset -  ornithine 
transcarbamylase deficiency -  OTC deficiency
Dr. 0. P. van Diggelen, Department of Clinical 
Genetics, Erasmus University, PO Box 1738, 
3000 DR Rotterdam, The Netherlands,.
Tel:: 31-10-408 7224. Fax: 31-10-408 7220
Received in revised version 29 April, 
accepted for publication 7 June 1996
Ornithine transcarbamylase (OTC; E.C. 2.1.3.3) is death. These patients have undetectable OTC activ- 
one of the enzymes required for detoxification of ity in liver (for review see: Brusilow & Horwich
waste nitrogen compounds, particularly ammonia. It 1995). An increasing number of males with OTC
catalyses the first step of the urea cycle: the synthe- deficiency with late onset, up to early adulthood, has 
sis of citrulline from carbamoyl phosphate and orni- been reported (Krieger et al. 1979, DiMagno et al.
1986, Oizumi et al. 1984, Holmes et al. 1987, Ca- 
vard et al. 1988, Finkelstein et al. 1990, Drogati et 
al. 1988, Matsuda et al. 1991, Tuchman & Holz- 
present with acute neonatal hyperammonemia lead- knecht 1991, Matsuura et al. 1993). The oldest d in ­
ing to coma and, in the absence of treatment, to early ically affected males with OTC deficiency were 46
thine. Deficiency of OTC is an X-linked, partially 
dominant trait with milder expression in females
Hemizygous males commonlyin
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Fig, 1. Pedigree of the family K. with late-onset OTC deficiency. ■: Clinically affected male patients; a black dot over tilled square? 
indicates the presence of A208T mutation in males. Q: obligate heterozygotes with confirmed A208T mutation. The MspI hapltuype 
of the OTC gene (Gl, G2 and G3) is indicated under each symbol and an N inside a symbol indicates the absence of the G2 allele car­
rying the A208T mutation. The MspI haplotypes of 1-9 and I—10 are in brackets, indicating that their presence has been deduced trom 
the extended haplotyping in 25 members of the family using 12 polymorphic markers at various distances from the OTC gene.
and 58 years (Matsuda et al. 1991). In this paper we The rapidly fatal course of the disease
report a five-generation pedigree with late onset with headache, nausea, abdominal pain, sometimes 
OTC deficiency caused by a new mutation which dizziness, and somnolence as the sequel to a viral or
could be traced to the index patients’ great-grandfa- bacterial infection with fever (angina ■Zfl
ther, who had never had episodes characteristic of sis, influenza, 01
OTC deficiency and died at age 59.
Patients and methods
rhoea). Usually within 1 or 2 days (except ease III 1 
where this period lasted 5 weeks), mental di.stur 
banc es appeared, ranging from t o
coma. , irriti
The pedigree of the family K is depicted in Fig. 1 sion) and euphoria were also noticed. At the same 
and the clinical signs and symptoms of the male time characteristic cerebellar signs developed: un- 
patients who died are summarised in Table 1. None certain gait and ataxia and seizures, as well as py-
of the females of the pedigree had clinical symptoms ramidal signs with spasticity. Eventually* 
of OTC deficiency. Six males of generation III died gressive loss of consciousness led to irrever
remarkably coma and death. Lymphopenia was a frequent laho
and 23 year (average 15.4 years). The disease struck ratory finding, probably caused by viral infections
apparently normal with good mental and During the acute phase which patient IV 7 survived,
physical capacities, even above average (III-19 was he developed a transient deficiency of T  helper lyin
one of the best socker players of his school and III an increase of T  suppressor lym
24 was junior tennis district champion). Four of phocytes (index Th/Ts«0.2). In case i l l - 19 the lym ■X;
them had no orevious history of simil
them 24).
phopenia was associated with lack of rosette-form
ing ability. These to
In generation IV, patient IV-7 had a similar clini- post-mortem observations of lymph nodes (see b e -
cal course to the patients of generation III, except 
that he was the only survivor of an acute episode of 
the disease. IV-16 died during infancy at 3 months 
and his clinical symptoms were reminiscent of fe­
males who are heterozygous for severe infantile apparent absenc
low).
The six patients of generation III were seen in six
als and a metabolic disease had not 
been considered because of the late onset and
previous f a t related
deficiency. These patients were the first in sodes. In retrospect, a more detailed analysis oí
isa.
whom hvnerammonemia histories revealed qi
*probably were caused by OTC deficiency (a total of 
seven episodes in three patients; see Table 1).
Post-mortem histological examination showed 
that the patients invariably had brain edema (Table 
1). In the six available cases (III-1, 3, 19, 23 and 14; 
IV-16) spongiform changes were found, in 11-24 as 
widespread status spongiosus of both grey and 
white matter. Cortical nerve cells and cerebellar 
Purkinje cells were lost, whereas the Bergman glia 
had proliferated. Severe and chronic acidophilic 
necrosis and ischemic changes of the nerve cells 
were present. In most cases intravascular clotting 
and numerous extravasations were seen.
Liver of four deceased patients was examined 
(III-3, 19, 23 and 24), generally showing necrotic 
areas, mainly central, and vacuolated hepatocytes. 
The portal area was often infiltrated with lymphoid 
cells and some hepatocytes were necrotic or vacu- 
olized. In some sections central or diffuse fibrosis of 
hepatic globules was present. The histopathology 
was typical of chronic hepatitis.
Atrophy of lymph nodes with sparse lymph folli­
cles or absence of germinal centers were observed 
in three cases (III—3, 19 and 24).
van Diggelen et al.
DNA analysis
Genomic DNA was extracted from peripheral leu­
kocytes using routine procedures (Miller et al.
1988). SSCP analysis was done on the Phast System 
(Pharmacia) as described (Kneppers et al. 1995) 
with the PCR-amplified DNA fragment using the 
primers described by Matsuura et al. (1993), except 
for exon 1 where primers were chosen from the 
sequence data of Hata et al. (1988): forward primer 
upstream in exon 1 (TTA GTT TTT AGG TGG 
CCC C) and reverse primer in intron 1 (AAC CCA 
AGT CTC TGA CCA TCA). The presence of the 
A208T mutation was confirmed by digestion with 
restriction enzyme Hhal according to the manufac­
turer’s instructions (New England Biolabs).
The intragenic MspI polymorphisms in the OTC 
gene were analyzed as described by Rozen et al. 
(1985). Exons were sequenced after PCR amplifica­
tion using the intron primers described by Matsuura 
et al. (1993). Exons 4 and 7+8 were amplified in the 
presence of 10% DMSO, except for exon 1, where 
the intron primers of Hata et al. (1988) were used.
Enzyme analysis
OTC and carbamoylphosphate synthetase (CPS ; ref­
erence enzyme) were determined as described by 
Nozum & Snodgrass (1976). OTC in control livers 
was 13-36 jimol/min/mg protein (n=7; mean=24). 
In the index patient IV-7, OTC activity was 0.8 
jamol/min/mg, whereas CPS activity was within the 
normal range.
Table 1. Clinical signs & symptoms and post- mortem observation
111-1 III-3 III-4 111-19 ill-23 III-24 IV—7 IV-16
Acute episodes
Age at fatal acute episode 23 y 23 y 14 y 14 y 6y 19 y 14 y 3 mo
Duration of fatal episode 6 wk 10 d 5 d 6 d 8 h 7 d 2d 10 d
Probable triggering event angina influenza food poisoning diarrhoea pertussis angina angina fever
Earlier severe episodes none none none none none none 12 y none
Possibly related milder none 7,13,23 y none none none 12,18,18 y 13 y none
episodes1’
Signs and symptoms
Abdominal pain — + + + — — + ?
Headache (nausea) 4* (+) ?(?) + (+) - (+) _ H + (+) + (+) ?(+)
Consciousness disturbances anxiety
aggression
confusion + + anxiety somnolent/
euphoric
+
Generalized seizures - + + - + - +
Pyramidal tract anomalies, + + + + + + mm* +
including decerebrate rigidity
Papilledema M M + + — — — - —
Differential diagnosis 














Brain edema, marked + + + +, herniations 
(transtentorial, 
foraminal)




1) Retrospective data, not mentioned in anamnesis during fatal episodes.
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Fig. 2. Restriction enzyme analysis for A208T mutation in exon 6 of OTC gene. PCR-mplilied exon 6 of the relevant members of 
family K. were digested with Hhal. The wild-type allele contains one Hhal site, leading to the formation of 102 bp and 58 bp frag­
ments. The A208T mutation destroys this site, leaving the PCR product of exon 6 intact ( 160 bp). O: Females heterozygous for the 
A208T mutation. A black dot over the male symbols indicates the presence of the A208T mutation in males.
Results
The pedigree of family K. (Fig. 1) presents an 
X-linked recessive trait with eight deceased male 
patients and eight asymptomatic female carriers. 
The clinical phenotype was remarkably similar (see 
Patients section and Table 1 ). Without clear prece­
dents, the mental and physical state of the patients 
deteriorated rapidly, resulting in coma, brain edema 
and death within 8 hours to 6 weeks. The first 7 
patients all died undiagnosed at ages 6-23 years, 
except IV-16 who died at infancy. This patient, the 
second to last who died, was the first case in which 
metabolic screening was done and hyperammone­
mia was found. This had been attributed to Reye
were then digested with this restriction enzyme and 
analyzed. Fig. 2 shows that the transmission of OTC 
deficiency in family K. is concordant with the segre­
gation of the A208T mutation. Two males with the 
A208T mutation did not have clinical symptoms 
(IV -14 and V-4), but OTC deficiency was con­
firmed by abnormal orotic acid elevations of the al-
2 < 1 L'lopurinol challenge
were not allowed by the parents). The mother of 
V-4, an obligate heterozygote, had slightly abnor­
mal orotic acid levels after allopurinol administra­
tion; her grandmother had completely normal re-
To exclude that the A208T substitution could be a
which by chance with
syndrome (frozen liver tissue from this patient and OTC deficiency, all exons of the OTC gene of the
the previous ones was not available). Before OTC 
deficiency was demonstrated, a variety of diagnoses 
were 
patient
index patient IV-7 and the preclinical patient IV--14
l). Only when the last 
patient IV-7), was Table 2. Allopurinol challenge test of two males with the A208T mutation and
available lor enzyme analysis and a severe OTC the corresponding heterozygotes
deficiency was demonstrated (3% of normal mean 
activity, see Methods section).
The search for the disease-causing mutation was 
started with SSCP analysis of the index patient’s 
DNA and the PCR product of exon 6 showed a 
bandshift (data not shown). Direct sequencing re­
vealed a GCA-»ACA mutation in codon 208, caus­
ing an Ala—>Thr substitution (A208T) and destruc­
tion of an Hhal restriction site. PCR-amplified frag­
ments of exon 6 from the available family members






Mother of V-4 (IV-6)
G reat-g ran d mothe r of V-4 (IM)
Oh 6 h 12 h 18 h
■ ».a.»*» 1.
1.9 99 51 1.7
3.9 39 30 11
1.4 7.8 3.4 1.4
0.7 1.0 0.7 0.5
n i iTwm pn < ur iit*|  iH in ifi>r iìr ■ ■tin~HiiiM»n>%ni»i»ii»vi>>i»‘i>ii■Hill ‘ r  * i t~''Trt~r<rrir>n-»-m ~ t - r i < i 8 » r • > " j •ivvs' *i “?****►*
11 j.ig/mmol creatinine; normal reference range: 1.2-3.2.
2) Dose of atiopurinof was 300mg.
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Table 3. Regions of the OTC gene sequenced: all 10 exons plus flanking intron 
boundaries
46 and 58 years (Mi 
K., described in Fig. I,
Exon1)
Length of fragment sequenced 
(position towards exon)2)
1 186 bp (~683) to +41)
2 202 bp (-30 to +33)
3 201 bp (-85 to +35)
4 111 bp (-8 to +15)
5 197 bp (-20 to +23)
6 164 bp (-20 to +30)
7+8 301 bp (-7 to +10)
9 224 bp (-7 to +10)
10 83 bp (-16 to +7)
a et al. 1991). The family
ogeneity of 
ause an asymptomatic malethe disease in males
of 59 was found and all heterozygous females were 
asymptomatic. of the
11 Intron and exon sequences were compared to Matsuura et al. (1993) and
Horwich et al. (1984).
21 -  Means upstream of exon and + means downstream.
3) Position upstream of start codon.
was ‘normal’ in the allopurinol challenge test. This 
confirms previous false negative results (Tsai et al. 
1991), and once more illustrates the limitations of 
this test for detecting heterozygotes.
It took 28 years before the diagnosis was estab­
lished in the family K. and it is of interest to analyze 
why it took so long. The first six patients who died 
at ages 6-23 years in a period of 15 years, were ad­
mitted to six different hospitals, which hampered 
comparison of the patients and recognition of the fa­
milial character of the disease. The X-linked inherit­
ance of this disease was recognized by one of the 
authors (J. Z.) when the last patient of generation III 
(111-24) died in a hospital with a clinical genetics de-
were sequenced, the flanking intron boundaries in- partment; the essential pedigree d
for 1 coding ible in a peripheral hospital years
quences). No other base changes were detected, ex- III—4
polymorphisms and discrepancies which died during the first episode of a disease
had already been reported in the literature. Then, which followed the course of increased intracranial
60 Dutch and 60 Polish control alleles pressure, coma and death. Initially, a metabolicfrom
was investigated by digestion with Hhal and the coma was not suspected because the clinical fea- 
A208T substitution was not found. These results in- tures of the patients led to admission to neurology
departments whichdicate that A208T is the disease-causing mutation.
Since no material from generation I was availa­
ble, we attempted to trace the origin of the mutation not performed.




CT scans and MRI
by determining the MspI haplotype in the offspring. brain tumor
The haplotypes of this intra-exonic polymorphism (at that time
of the OTC gene are shown in the pedigree (Fig. 1). two cases were suspected of encephalitis and one of
All obligate heterozygotes and the affected males acute intermittent porphyria (see Table 1). The fa-
have the G2 haplotype. Both normal males in gener­
ation II have the G3 allele, making this polymor- ia f ï t1 ti\ a 3k
cter of the dis- 
of the health of
phism uninformative. We then screened 12 poly- the patients prior to the fatal episode, and in only
morphisms at various distances from the OTC gene, three out of eight patients had
looking for crossing-over events in 25 members of probably disease related, occurred (Table 1 ; overall 
family K. The haplotypes of the 12 markers proved seven episodes in three patients). When the 7th pa-
that the G2 OTC allele carrying the mutation must 
have been of paternal origin (1-9).
tient (IV-16) died, again in a different hospital, hy­
perammonemia was
Discussion
In the last two decades it has become apparent that 
the clinical course of OTC deficiency in males is 
very heterogeneous. The classical form with neona-
suspected. Liver tissue was not available for enzy­
matic analysis. By then, the striking clinical similar­





s in ! ;ases,
tal onset and hyperammonemic coma is generally lethargy and coma). Some of oui
well recognised, but the late-onset forms can
ilso re­
sembled a 29-vear-old male with bizarre behavior
(Matsuda et al. 1991)
al.
reported by DiMagno et al. (1986). Interestingly, at
reported that only about 50% of their the age of 16 years this case was suspected of Gil-
patients had onset in the neonatal period. Onset in bert syndrome, like our case 111-24.
the remaining half of their male patients was after
adulthood
oldest reported patients with an acute episode were
Liver became available for OTC 
for the first time when the index patient IV-7 had his
acute and fatal episode of the disease. The
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residual activity was only 3% under saturating con- ularly in small families. This adds a new dimension
ditions.
At present approximately 70 different mutations, 
including polymorphisms, are known leading to var­
ious degrees of OTC deficiency (Tuchman et al.
to the existing heterogeneity of OTC deficiency.
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